• Products
  • Suppliers
  • Sourcing Requests
  • capsule
  • Paracetamol
  • Dexamethasone
  • semaglutide
  • peptides
  • Metformin
  • Ritonavir
  • Ibuprofen
  • Yaan Times Biotech Co., Ltd
  • Changsha Staherb Natural Ingredients Co., Ltd.
  • PURELIFE BIOTECH CO.,LTD.
  • Biocompounds Pharmaceutical Inc.
  • Xi'an Kaixiang Photoelectric Technology Co., Ltd
  • Apollo Healthcare Resources (Singapore)
  • Shanghai UFU Laboratory Equipment Co.,Itd
  • GN Chemicals CO,Ltd.
Post Sourcing Request Exhibition
  • Cyxone Inks API Deal with European CDMO contractpharma
    January 20, 2022
    Takes next step in multiple sclerosis program engaging CDMO for production of drug candidate T20K.
  • Cyxone appoints Henrik Hang as CFO firstwordpharma
    June 10, 2021
  • Cyxone Explores Orphan Drug Designation for Rabeximod americanpharmaceuticalreview
    September 09, 2019
  • Cyxone Submits First Application to Start Rabeximod Clinical Trial americanpharmaceuticalreview
    July 08, 2019
    Cyxone has submitted an application to the Central Ethics Committee (CEC) in Poland for permission to start a clinical phase IIb trial with its drug candidate Rabeximod, which is in development for the treatment of rheumatoid arthritis (RA).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service